Novel perspectives on dendritic cell-based immunotherapy of cancer

被引：35

作者：

Bonaccorsi, Irene ^{[1
,2
]}

Pezzino, Gaetana ^{[1
,2
]}

Morandi, Barbara ^{[3
]}

Ferlazzo, Guido ^{[1
,2
]}

机构：

[1] Univ Messina, Dept Human Pathol, Lab Immunol & Biotherapy, I-98125 Messina, Italy

[2] Univ Hosp AOU Policlin, Cellular Therapy Program, Messina, Italy

[3] Univ Genoa, Dept Expt Med DIMES, I-16126 Genoa, Italy

来源：

IMMUNOLOGY LETTERS | 2013年 / 155卷 / 1-2期

关键词：

Dendritic cells; Cancer vaccines; Immunotherapy; Lymph; Cell interactions; SERUM-FREE CONDITIONS; NATURAL-KILLER-CELLS; NK CELLS; CLINICAL-RESPONSES; ANTITUMOR IMMUNITY; IFN-GAMMA; METASTATIC MELANOMA; LYMPHOID-TISSUES; FLT3; LIGAND; T-CELLS;

D O I：

10.1016/j.imlet.2013.09.021

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

071005 [微生物学]; 100108 [医学免疫学];

摘要：

Advances in immunobiology knowledge as well as in cell culture processes that generate large numbers of purified and functionally mature dendritic cells (DCs) have raised the possibility that DCs might represent promising clinical agents to generate effective immune responses against cancer. Here, we discuss the present pitfalls of dendritic cell vaccines for the treatment of human cancer with regard to the most recent knowledge in the biology of DCs. In particular, we highlight the relevance of improving our current understanding of DC trafficking, functions and interactions with other cells of innate immunity for the development of more effective cancer vaccines. (C) 2013 Elsevier B.V. All rights reserved.

引用

页码：6 / 10

页数：5

共 41 条

[1]

DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction [J].